期刊
LEUKEMIA RESEARCH
卷 52, 期 -, 页码 20-27出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2016.11.002
关键词
Myelodysplastic syndrome; Erythropoietin; Immune modulation; T cells; Lymphocytes
资金
- Israel Cancer Association
The immune system is impaired in myelodysplastic syndromes (MDS) and plays a role in the pathogenesis of the disease. Here we show effects of recombinant human erythropoietin (rHuEPO) on T cell (CD4(+), CD8(+) and CD4(+)CD25(+)) number and function in MDS patients. Healthy (20 subjects), MDS patients without rHuEPO treatment ('MDS', 13), and MDS patients treated with rHuEPO ('MDS+EPO', 17) were examined. CD4(+) and CD8(+) T cell numbers were reduced and increased respectively in MDS compared to healthy subjects. EPO treatment normalized these levels. CD4(+)CD25(+) cell numbers, lower in MDS, were normalized in MDS+EPO. In vitro activation of CD4(+) and CD8(+) cells with phytohemagglutinin as measured by CD69 expression, demonstrated a 7.2 fold increase in CD4(+) activation vs 13.6 fold for MDS and MDS+EPO respectively (p=0.004); and 10.2 fold (MDS) vs 18.6 fold (MDS+EPO, p < 0.003) for CD8(+) T cells. Expression of the co-stimulatory marker CD28, decreased in CD4(+) and CD8(+) T cells in MDS, was normalized in MDS+EPO CD4(+) T cells. Subgroup analysis of milder disease (WHO RA and RARS) and more advanced disease revealed no difference in CD4(+) and CD8(+) T cell numbers. However, the activation of these cells in the RA/RARS subgroup was impaired in EPO-untreated and enhanced in EPO-treated MDS patients. Our data suggest that EPO treatment improves immune abnormalities in MDS and may depend on disease severity. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据